SLIDE 1
- !
- "##$
Market Consistent Embedded Value 1 - - PowerPoint PPT Presentation
Market Consistent Embedded Value 1 - - PowerPoint PPT Presentation
Market Consistent Embedded Value 1
SLIDE 2
SLIDE 3
- !"#
$%&'
- %&'#
- (##"
(
- )
- *+,-.'" %/
#()*
SLIDE 4
- +(' ,%-./
+0)(,.-1.)) !)
2
- /1$
/$31 .413 0# $13 $1 /$3313 5#6 4$1 6 %-./1 ++7 %%/1
- "#
, .-1. /%1- %14 0# //14& /13& /13& 0#85" + 6
- ,
SLIDE 5
SLIDE 6
- "#
- !"#
$%&
- &
'( )
*
- +
- *
- $%& !" (,-
SLIDE 7
- .
0#
- 0#91)
:5#6 ;
- 6(<=
- 0#)
- 0%#
- 1$
- 123
- 12$-
#-3
SLIDE 8
- /
9(
- "!
- !$+,4%$ #/
- 0%$!+
- #5
- *+-$ 6 $$7*$
- 11
- 3
SLIDE 9
- ><'=
>
(
78 #% -
- + %
- 1!
*+9#$!# :*+9%%+ *+ ++ +
SLIDE 10
- 12
0)(
- +
- #%$%#$
- 6()(
!;
- (;
SLIDE 11
- 11
- "!
!8$# 33 *3;4:4:,4'<<' =/ )8$## $,4.'/ 8$#% $;4>4> +$;4>4>
- 3,75%
3,80% 3,85% 3,90% 3,95% 4,00% 4,05% 4,10% 4,15% 4,20% 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29
SLIDE 12
- 1
"#.>
- "#31-&.
- !
- 4?;-;'=-',3 4'/
- !314<-.',3'/
.
- ANAV
2 528 M€ ANAV 2 528 M€
CE 2 791 M€
MCEV 4 462 M€
- ther risks 99 M€
FOG 416 M€ CoC 344 M€ MCEV MCEV
VIF 1 933 M€
- ther risks
FOG CoC CoC
ANAV 2 308 M€ ANAV 2 308 M€ MCEV 3 414 M€
- ther risks 101 M€
FOG 307 M€
CE 1 828 M€
MCEV MCEV
VIF 1 107 M€
- ther risks
FOG CoC 313 M€ CoC
SLIDE 13
- 1
0)(
0)(,%31/13& 5"1/1&5#5 +()?
;;4 ) ),))/ =4< )!$ ,)/ %3 0)( 9.
- + +
94. 7 " @; !$ 0# ,
SLIDE 14
- 1
( "#
43/ .$/ % # 333 //. 44 "@ ( 3/8/8 =; <& 9; 0%#$ = 9& 44 $ % 94;. 9 94;. A$ . 3%/% // 34 # 3/8/8. 9 9 9 5 .4 * < 0# /$3% 3- .4; #6 3- < = %% # 3/8/8 <@& 7 "# ,
- 5(@,-4$1@?
- *$++
- *$5,+/:
5(,3-1?
- #%.,4#;-;'=-'/
SLIDE 15
- 1
"#(
(1) (2) (3)=(1)+(2) MCEV Sensitivities - Inforce Value 2006 (M€) Change in ANAV Change in VIF Change in MCEV Change in MCEV as a % of the central MCEV Risk free rate -100 basis points 59
- 725
- 666
- 14%
Risk free rate +100 basis points
- 59
426 368 8% Equity and property values -10%
- 90
- 297
- 387
- 8%
Equity and property values +10% 90 283 373 8% expenses + 10%
- 155
- 155
- 3%
lapse rates -10% 42 42 1% Mortality (annuities) -5%
- 33
- 33
- 1%
Mortality (other products) -5% 37 37 1% Other claim ratios - 5% 129 129 3%
SLIDE 16
- 1
0)((
- 4'
&- 7*/& 9.' 9-; <=*.& 9.&' 9.-4 "@ A/& @-< 9- =-. 9-@
0#B 0#
' 94' 44' 9.;'
0# & 0#
2! */ < =*.& *.& 2! A/
,
SLIDE 17
- 1.
"#?
6?
- +<:
91=) ( 0)
- :1()
SLIDE 18
- 1/
6
SLIDE 19
- 10
2! 6 :
!8@' )8.-.' *8;-.'
"
)
- <'
- 44'
4' 4;' 4=' 4.' 4.' 4.' 4<' ;' *+ 4.1 4= 4; 4 44 4 & @ < =-=' =-=' =-@' ) =-.' =-.' =-4;'
- =-..'
=-..' =-=;'
- @'
&' 4' 44' 4' 4' 4' 4=' ' *+ 4.1 4= 4; 4 44 4 & @ <
6
SLIDE 20
- 2
" #
44&- &-= ;@-. @-4 =;- )#
- 9;-
9-@ 9@-& 9.-4 9@-
- 431%
3%14 %41
- %-1/
31 %1/ 5 /$31 3.1 4.1$ 0# $1 41 $1 5#6
- %31
+! 4$1 ++7 //.1. 6 "# ,
6
SLIDE 21
- 1
0)#
$1 ;;- &- 44-4 4.-4 5"
- /13&
4&-;' 4-' ;-' ;-@' 5" ;-@' &=-= ;-
- ;-='
44-< ;-. 5 /%1-
- .
4-4 0# %/1$ 444-4 4.-< 5#5 .-@' +! 31& ++7 4-' 6 0#85#5 ,
6
SLIDE 22
- "#(
- @
- /&7
9-< 94-& 94-4 94- 6 /&"@ 9-@ 9;-4 94@-& 9&-;
BBB
/ ( <) =
- ;
4;- ;-; 9-@ 5
- 4-.
;-= 9;-4 6 9- 9=-= / ! 2
- =-=
/ ! 2 4-; 4-< @-<
BBB
- 4-
- @
+!
C
.& .&2 CC / ( <) = ,
B"%,-.'/ BBC#.'
BBB" - 4# % $
$
6
SLIDE 23
- 0)((
- 4
- =
/&7 9-& 9-; 9- 9-= 6 /&"@ 9-; 9-4 9;- 9-4
BBB
/ ( <) =
- <
9- 5
- 4
- 4
- =
9-; 6 9-= 9-< / ! 2
- =
- <
/ ! 2
- ;
- 4
BBB
- 4-@
- ;
+!
C
.& .&2 CC / ( <) = ,
B"%,-.'/ BBC#.'
BBB" - 4# % $
$
6
SLIDE 24
- DE$$%-
$# ": 7%+%% :E$ #": #$-% %!#)# #7-+# #$$##AF : *#$# $# 5% %+# ,*#/: *#$+%
- -3-%
#F:% CGEA#$#-3 $#$- $#:A$3# 3H:
* >
SLIDE 25
SLIDE 26
- #
629
In M€ International France
Total
Value of inforce 96 1 955
2 051
Deferred acquisition cost
- 4
- 46
- 50
Unrealised gains included in shareholder's equity
- 46
- 1 344
- 1 390
Unrealised gains included in ANAV 14 387
401
VOBA
- 33
- 33
Other adjustements 26
26
holding expenses
- 105
- 105
Additional value not accounted for in IFRS shareholders' equity 27 872 899
3 %
SLIDE 27
- .
'(
0# 850: 5" 82)!$:%#$-!4' 4' 5" 80C$#): " 8!$:*$93-5$ #I%$+9 : 8 ' 87G": 0# 80%C:*$%#- +: 5#6?): !$ G- + 5#58)):%#$-!$ 3#$$ :